Association of body composition and systemic inflammation for patients with locally advanced cervical cancer following concurrent chemoradiotherapy

被引:0
|
作者
Li, Juan [1 ]
Niu, Cuili [1 ]
Zhang, Ling [1 ]
Mu, Yanmin [1 ]
Gui, Xiuyin [1 ]
机构
[1] Xingtai Third Hosp, Clin Gynecol, Xingtai, Peoples R China
来源
关键词
Cervical cancer; concurrent chemoradiotherapy; systemic inflammation; body composition; prognosis; VISCERAL FAT PERCENTAGE; PROGNOSTIC VALUE; SARCOPENIA; OBESITY; PREDICTION; MARKERS; CELLS;
D O I
10.4274/dir.2024.242751
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE Systemic inflammation and body composition are associated with survival outcomes of cancer patients. This study aimed to examine the combined prognostic value of systemic inflammatory markers and body composition parameters in patients with locally advanced cervical cancer (LACC). METHODS Patients who underwent concurrent chemoradiotherapy (CCRT) for LACC at a tertiary referral teaching hospital between January 2010 and January 2018 were enrolled. A predictive model was established based on systemic immune-inflammation index (SII) and computer tomography-derived visceral fat-to-muscle ratio (vFMR). Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method and Cox regression models. The model performance was assessed using discrimination, calibration, and clinical usefulness. RESULTS In total, 212 patients were enrolled. The SII and vFMR were closely related, and both independently predicted survival (P < 0.05). A predictive model was established based on the above biomarkers and included three subgroups: high-risk [both high SII (>828) and high vFMR (>1.1)], middle-risk (either high SII or high vFMR), and low-risk (neither high SII nor high vFMR). The 3-year OS (PFS) rates for low-, middle-, and high-risk patients were 90.5% (86.0%), 73.9% (58.4%), and 46.8% (36.1%), respectively (P < 0.05). This model demonstrated satisfactory predictive accuracy (area under the curve values for predicting 3-year OS and PFS were 0.704 and 0.718, respectively), good fit (Hosmer-Lemeshow tests: P > 0.05), and clinical usefulness. CONCLUSION Systemic inflammatory markers combined with body composition parameters could independently predict the prognosis of patients with LACC, highlighting the utilization of commonly collected indicators in decision-making processes.
引用
收藏
页码:279 / 290
页数:12
相关论文
共 50 条
  • [1] Prognostic Value of Body Composition and Systemic Inflammatory Markers in Patients with Locally Advanced Cervical Cancer Following Chemoradiotherapy
    Guo, Hui
    Feng, Shuai
    Li, Zhiqiang
    Yin, Yueju
    Lin, Xueying
    Yuan, Lingqin
    Sheng, Xiugui
    Li, Dapeng
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 5145 - 5156
  • [2] Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
    Guo, H.
    Feng, S.
    Yin, Y.
    Li, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1591 - S1591
  • [3] Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer
    Kim, Ja Young
    Byun, Sang Jun
    Kim, Young Seok
    Nam, Joo-Hyun
    GYNECOLOGIC ONCOLOGY, 2017, 144 (01) : 34 - 39
  • [4] Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer
    Jakubowicz, J.
    Blecharz, P.
    Skotnicki, P.
    Reinfuss, M.
    Walasek, T.
    Luczynska, E.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2014, 35 (04) : 393 - 399
  • [5] Adjuvant hysterectomy in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Shim, Seung-Hyuk
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (03)
  • [6] Operation for locally advanced cervical cancer after concurrent chemoradiotherapy
    Junli Ge
    Jidong Sun
    Jia Li
    Qianfeng Zhang
    Xiaohui Lv
    Biliang Chen
    International Journal of Clinical Oncology, 2020, 25 : 948 - 954
  • [7] Operation for locally advanced cervical cancer after concurrent chemoradiotherapy
    Ge, Junli
    Sun, Jidong
    Li, Jia
    Zhang, Qianfeng
    Lv, Xiaohui
    Chen, Biliang
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 948 - 954
  • [8] Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
    Kadkhodayan, Sima
    Shandiz, Fatemeh Homaei
    Toussi, Mehdi Seilanian
    Aghaee, Monavar Afzal
    Farshidi, Farnoosh
    Dehghan, Parvane
    IRANIAN JOURNAL OF CANCER PREVENTION, 2013, 6 (04) : 195 - 200
  • [9] Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Jing Liu
    Guyu Tang
    Qin Zhou
    Weilu Kuang
    Radiation Oncology, 17
  • [10] Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Liu, Jing
    Tang, Guyu
    Zhou, Qin
    Kuang, Weilu
    RADIATION ONCOLOGY, 2022, 17 (01)